Insulin-like growth factor-binding protein-1 and prostate cancer

Journal of the National Cancer Institute

Volumn 91, Issue 22, 1999, Pages 1965-1967

  Signorello, Lisa B ^a,b   Brismar, Kerstin ^c   Bergstrom, Reinhold ^e   Andersson, Swen Olof ^e   Wolk, Alicja ^e   Trichopoulos, Dimitrios ^d   Adami, Hans Olov ^e  

^a KAROLINSKA INSTITUTE   (Sweden)

^b INTERNATIONAL EPIDEMIOLOGY INSTITUTE   (United States)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d HARVARD CENTER FOR CANCER PREVENTION   (United States)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN BINDING PROTEIN 1;

AGED; ARTICLE; CANCER RISK; CARCINOGENESIS; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; REGRESSION ANALYSIS;

EID: 0033579132     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/91.22.1965     Document Type: Article

References (23)

1. Burfeind P, Chernicky CL, Rininsland F, Ilan J, Ilan J. Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo. Proc Natl Acad Sci U S A 1996;93:7263-8.
2. Cohen P, Peehl DM, Lamson G, Rosenfeld RG. Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells. J Clin Endocrinol Metab 1991;73:401-7.
3. Kimura G, Kasuya J, Giannini S, Honda Y, Mohan S, Kawachi M. et al. Insulin-like growth factor (IGF) system components in human prostate cancer cell-lines: LNCaP, DU145, and PC-3 cells. Int J Urol 1996;3: 39-46.
4. Torring N, Vinter-Jensen L, Pedersen SB, Sorensen FB, Flyvbjerg A, Nexo E. Systemic administration of insulin-like growth factor I (IGF-I) causes growth of the rat prostate. J Urol 1997;158:222-7.
5. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998; 279:563-6.
6. Mantzoros CS, Tzonou A. Signorello LB, Stampfer M, Trichopoulos D, Adami HO. Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer 1997;76:1115-8.
7. Wolk A, Mantzoros CS, Andersson SO, Bergstrom R, Signorello LB, Lagiou P, et al. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst 1998;90:911-5.
8. Thrasher JB, Tennant MK, Twomey PA, Hansberry KL, Wettlaufer JN, Plymate SR. Immunohistochemical localization of insulin-like growth factor binding proteins 2 and 3 in prostate tissue: clinical correlations. J Urol 1996;155:999-1003.
9. Drivdahl RH, Loop SM, Andress DL, Ostenson RC. IGF-binding proteins in human prostate tumor cells: expression and regulation by 1,25-dihydroxyvitamin D3. Prostate 1995; 26:72-9.
10. Figueroa JA, De Raad S, Tadlock L, Speights VO, Rinehart JJ. Differential expression of insulin-like growth factor binding proteins in high versus low Gleason score prostate cancer. J Urol 1998;159:1379-83.
11. Ho PJ, Baxter RC. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia. Clin Endocrinol 1997;46:333-42.
12. Nunn SE, Gibson TB, Rajah R, Cohen P. Regulation of prostate cell growth by the insulin-like growth factor binding proteins and their proteases. Endocrine 1997;7:115-8.
13. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995;16:3-34.
14. Collett-Solberg PF, Cohen P. The role of the insulin-like growth factor binding proteins and the IGFBP proteases in modulating IGF action. Endocrinol Metab Clin North Am 1996;25:591-614.
15. Bar RS, Boes M, Clemmons DR, Busby WH, Sandra A, Dake BL, et al. Insulin differentially alters transcapillary movement of intravascular IGFBP-1, IGFBP-2 and endothelial cell IGF-binding proteins in the rat heart. Endocrinology 1990;127:497-9.
16. Lewitt MS, Saunders H, Cooney GJ, Baxter RC. Effect of human insulin-like growth factor-binding protein-1 on the half-life and action of administered insulin-like growth factor-I in rats. J Endocrinol 1993;136:253-60.
17. Povoa G, Rodvete A, Hall K. Cross-reaction of serum somatomedin-binding protein in a radioimmunoassay developed for somatomedin-binding protein isolated from human amniutic fluid. Acta Endrocrinol (Copenh) 1984;107:563-70.
18. Underwood LE, Thissen JP, Lemozy S, Ketelslegers JM, Clemmons DR. Hormonal and nutritional regulation of IGF-1 and its binding proteins. Horm Res 1994;42:145-51.
19. Brismar K, Hall K. Clinical application of IGFBP-1 and its regulation. Growth Regul 1993;3:98-100.
20. Clemmons DR. IGF binding proteins: regulation of cellular actions. Growth Regul 1992;2:80-7.
21. Kanety H, Madjar Y, Dagan Y, Levi J, Papa MZ, Pariente C, et al. Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen. J Clin Endocrinol Metab 1993;77:229-33.
22. Ruoslahti E, Pierschbacher MD. New perspectives in cell adhesions: RGD and integrins. Science 1987;238:491-7.
23. Jones JI, Gockerman A, Busby WH Jr, Wright G, Clemmons DR. Insulin-like growth factor binding protein 1 stimulates cell migration and binds to the α5β1 integrin by menas of its Arg-Gly-Asp sequence. Proc Natl Acad Sci U S A 1993;90:10553-7.